Gammagard addendum: BAX rose only 1.7% today because: i) there remains a high degree of skepticism about the pending phase-3 trials; and ii) it’s unclear how profitable Gammagard for AD would be for BAX due to the high manufacturing cost and the weak IP.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”